What is cancer most afraid of? When surgery, radiotherapy, and chemotherapy are all infeasible, what other options are there?

     

In November 2024, Mr. Chen suddenly experienced hematuria, and underwent MRexamination, which confirmed bladder cancer; PET-CTshowed: thickening of the anterior superior wall of the bladder, local edge calcification, and increased abnormal metabolism; Multiple enlarged hypermetabolic lymph nodes are found in the retroperitoneum, beside the bilateral iliac vessels, on the pelvic wall, and in the bilateral inguinal regions; Considering comprehensively, bladder cancer with multiple lymph node metastases is highly probable.

   

In December 2024, , cystoscopy revealed multiple tumors in the bladder. Solid neoplastic lesions were observed in the trigone, left lateral wall, posterior wall, and dome wall, with sizes ranging from 1-4cm.

Pathological report: (Bladder tumor)Low-differentiated carcinoma, combined with immunohistochemical results, considered as Bladderhigh-grade invasive urothelial carcinoma, no muscularis propria layer found, biopsy tissue limited, please consider clinically.

After Mr. Chen was diagnosed, he had planned to undergo surgery after the Spring Festival in February 2025. However, during the waiting period for the surgery, he suddenly developed a heart problem and had a pacemaker implanted. Considering that Mr. Chen was already 80 years old and had underlying diseases, this made the planned bladder cancer surgery difficult and infeasible.

Helplessly, he had to choose half-dose chemotherapy. However, the day after chemotherapy, Mr. Chen developed high fever 39~40℃, and was diagnosed with nephritis. Emergency anti-inflammatory and fever-reducing treatment was administered . Due to intolerance, Mr. Chen's chemotherapy treatment path was once again blocked.

Currently, radiotherapy is the only remaining option among the three main cancer treatments. However, Mr. Chen's bladder cancer, which is mostly urothelial carcinoma, accounts for 90% of all bladder malignancies, and it belongs to the type of solid tumors that are relatively insensitive to radiotherapy with strong repair capabilities of cancer cells. If radiotherapy is used, higher doses are required to achieve therapeutic effects, but high doses may exacerbate damage to normal tissues, with significant side effects, high recurrence rates, and limited long-term efficacy^[1-2]. Therefore, doctors do not recommend radiotherapy.

Case interpretation by Professor Zhang Minghui's team

When conventional cancer treatments fail, can some new drugs and therapies provide patients with more possibilities？Professor Zhang Minghui helps patients find hope in despair.

Mr. Chen's immunohistochemical results provide insights into: CK20(partially +), CK7(+) , CK5/6(focally +), GATA-3(partially +), p63(focally +), HER-2(2+) , NKX3.1(-), Syn(-), INSM1(-), S0X-10(-), PAX-8(-), PDL1(SP263)(CPS:25).

HER-2(2+), This protein is positive, which on the one hand suggests that this bladder cancer patient may have a higher degree of malignancy and a worse survival rate; but from a treatment perspective, if FISH confirms amplification, the patient may benefit from anti-HER-2 targeted drugs.

PDL1(SP263)(CPS:25)，indicates that there are 25positive cells per 100 tumor cells, suggesting a high expression of PD-L1in the tumor microenvironment, which may make the tumor cells more sensitive to PD-1/PD-L1inhibitors. This may become another breakthrough in Mr. Chen's treatment.

If you are experiencing similar treatment difficulties, Professor Zhang Minghui's Lehe New Medical Team[Second Diagnosis and Treatment Opinion]can support personalized treatment plans for you, and professional strength can help you find the most suitable survival strategy.

   

     

Lian

is a

I

   

Scan QR code

Communicate with Professor Zhang Minghui's team

     

Zhang Minghui      

Founder of Lehe New Medicine

Professor Zhang Minghui, who holds a PhD in Immunology from Tsinghua University School of Medicine, has led a research team for over 20 years since the discovery of vNKT cells in 2002. They have accumulated experience in treating over 700 cases of solid tumors, covering almost all common solid tumors. The research results fully demonstrate the great value of vNKT cells in the treatment of solid tumors.

It is suitable for postoperative patients with high pathological malignancy or a risk of recurrence; patients whose tumors have been basically controlled but not cured through conventional treatments such as chemotherapy, radiotherapy, and targeted therapy; patients with persistent high carcinogenic factors; and patients intolerant to radiotherapy and chemotherapy. If these patients do not receive effective follow-up treatment after traditional anti-tumor therapy, recurrence, metastasis, or reoccurrence of tumors will be highly probable. In this case, vNKT cell therapy is an ideal follow-up treatment method that can significantly improve the prognosis of patients.

Written by Zhang Tuo  

Reviewed by: Qiao Jiacheng, Wang Ying, Gao Chen

Edited/typeset by Zhang Jiao

Click on the image to view past exciting content

             

             

       

         

             

What the fairies are watching

Click on the upper right corner of the homepage · Set as Starred !